As the third most common disease in the world, you’d think there would be a cure for migraines by now.
Roughly 1 in 7 Americans are affected by these annoying headaches in one way or another and there isn’t much to do about it.
But Biohaven Pharmaceuticals has plans to change that…
Even if you don’t personally deal with these aches and pains, squashing migraines once and for all isn’t the only thing that Biohaven Pharmaceuticals has to bring to the table.
Ever since Wall Street caught wind of the progress that the company has been making towards finding a cure, BHVN’s stock price has DOUBLED!
Here’s an easy way to piggyback off Biohaven’s success and earn yourself some easy cash in the process.
Obviously getting in on all these profits requires and investment in BHVN. Just don’t let the $50 price tag scare you away…
According to the technical side of things, shares are heading for a strong bull run!
Take a look at the chart below.
You don’t have to be a pro at technical analysis to realize that Biohaven Pharmaceutical’s stock has been climbing up since the start of 2019.
As I write this, more than $10 have been added to individual share prices in less than 24 hours!
An increase like that is well over 20%. The S&P 500 doesn’t even come close to half of that after an entire year!
That’s only if you’re looking at the short term though…
Between the holiday season and now, BHVN values have increased 100%!
In other words, prices have DOUBLED over the course of 4 months.
But why? What caused Biohaven’s stock to suddenly shoot for the starts?
One explanation is the fact that BHV-3500, the code name for the drug that’s currently being developed by Biohaven to treat migraines, is in phase 2 of 3 in testing.
Considering BHV-3500 has already made it past the first round of trials is a great indication for the company.
And if all continues to go as planned, then the migraine cure could hit the shelves before we know it!
We’ve already seen solid price hikes in the market from the possibility of this migraine cure becoming a reality.
I can only imagine what kind of surge we’ll be up against once this drug makes it out of the final round of testing…
Let’s just say you’ll want to be a shareholder in the event of BHV-3500 getting approved.
Scanning the market for the perfect investment opportunity can sometimes make your head hurt, but BHVN is here to fix that both literally and figuratively.
If you’re looking for some easy profits, then go ahead and hop in a trade with Biohaven Pharmaceuticals.
Even though stock prices have already DOUBLED thus far, they’re expected to increase more and you don’t want to miss out on all the takings.
